EMA Investigates Potential Suicidal Thoughts Risk in Weight-Loss Medicines

No conclusion can be drawn yet on a causal association, with further discussions planned for April 2024.

The European Medicines Agency (EMA) is investigating the potential risk of suicidal thoughts associated with a new class of weight-loss medicines, including Novo Nordisk's Ozempic and Wegovy.
The EMA's safety committee has reviewed all clinical trial evidence and published literature on the subject, but no conclusion can be drawn on a causal association yet.
The EMA has asked pharmaceutical companies for more information and will discuss the topic again at its meeting in April 2024.
The investigation also includes other drugs such as Eli Lilly's diabetes medicine Trulicity, and AstraZeneca's diabetes drug Byetta.
The FDA-approved label of weight-loss drug Wegovy in the United States says suicidal thoughts or attempts have been reported in clinical trials for other weight-loss medicines.